Apolipoprotein A-I(R151C)(Paris) is defective in activation of lecithin: Cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux

Journal of Molecular Medicine

Volumn 77, Issue 8, 1999, Pages 614-622

  Daum, Ulrike ^a   Langer, Claus ^a   Chirazi, Ali ^a   Cullen, Paul ^a   Assmann, Gerd ^a   Von Eckardstein, Arnold ^a   Duverger, Nicolas ^b   Emmanuel, Florence ^b   Benoit, Patrick ^b   Denèfle, Patrice ^b   Pritchard, P Haydn ^c   Bruckert, Eric ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SANOFI   (France)

^c ST PAUL S HOSPITAL   (Canada)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

ApoA I variants; Cholesterol efflux; Familial hypoalphalipoproteinemia; LCAT; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANIMAL CELL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVATION; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN DEFECT; SWINE;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; AMINO ACID SUBSTITUTION; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EMULSIONS; ENZYME ACTIVATION; LIPID METABOLISM; LIPIDS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PROTEIN BINDING; RECOMBINANT PROTEINS; SWINE;

EID: 0032861594     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001099900034     Document Type: Article

References (45)

1. 1. Gordon D, Rifkind BM. Current concepts (1989) High density lipoproteins: the clinical implications of recent studies. N Engl J Med 321:1311-1315
2. 2. Plump AS, Scott CJ, Breslow JL (1994) Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 91:9607-9611
3. 3. Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, Fruchart JC, Branellec D, Denefle P, Duverger N (1999) Somatic gene transfer of human ApoA-1 inhibits atherosclerosis progression in mouse models. Circulation 99:105-110
4. 4. Brouilette CG, Anantharamaiah GM (1995) Structural models of human apolipoprotein A-I. Biochim Biophys Acta 1256: 103-129
5. 5. Oram JF, Yokoyama S (1997) Apolipoprotein-mediatcd removal of cellular cholesterol and phospholipids. J Lipid Res 37:2473-2491
6. 6. Funke H (1997) Familial HDL deficiency syndromes. In: Jacotot B, Mathe D, Fruchart JC (eds) Atherosclerosis XI. Excerpta Medica vol. 1155, Elsevier Science, Singapore, pp 713-731
7. 7. Gualandiri V, Franceschini G, Sirtori CR, Gianfranceschi G, Orsini GB, Cerrone A, Menotti A (1988). A-I Milano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 37:1083-1097
8. Milano inhibits carotid thickening induced by perivascular manipulation in rabbits. Circ Res 76:405-410
9. 9. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B (1998) Effects of rccombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97:780-785
10. Milano. Disulfide linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. J Biol Chem 265:12224-12231
11. Milano variant. Biochim Biophys Acta 960:73-82
12. Milano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme. Biochim Biophys Acta 1043:1-6
13. Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest 91:1445-1452
14. Milano. Atherosclerosis 128:121-128
15. 15. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353
16. 16. Mezdour H, Clavey V, Kora I, Koffigan M, Barkia A, Fruehart JC (1987) Anion-exchange fast protein liquid Chromatographic characterization and purification of apolipoproteins A-I, A-II, C-I, C-II, C-II10, C-II11, C-II12 and E from human plasma. J Chromatogr 414:35-45
17. 17. von Eckardstein A, Walter M, Benninghoven A, Assmann G (1991) Site specific methionine sulfoxide formation is the structural basis of Chromatographic heterogeneity in apolipoproteins A-I, C-II, and C-III. J Lipid Res 32:1465-1476
18. 18. Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
19. 19. Bergeron J, Frank PG, Emmanuel F, Latta M, Zhao Y, Sparks DL, Rassart E, Denefle P, Marcel YL (1997) Characterization of human apolipoprotein A-I expressed in Escherichia coli. Biochim Biophys Acta 1344:139-152
20. 20. Frank PG, Bergeron J, Emmanuel F, Lavigne JP, Sparks DL, Denefle P, Rassart E, Marcel YL (1997). Deletion of central α-helices in human apolipoprotein A-I; effect on phospholipid association. Biochemistry 36:1798-1806
21. 21. Jonas A, von Eckardstein A, Kezdy K, Steinmetz A, Assmann G (1991) Structural and functional properties of reconstituted high density lipoprotein discs prepared with six apolipoprotein A-I variants. J Lipid Res 32:98-109
22. 22. Huang Y, von Eckardstein A, Assmann G (1993) Cell-derived cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb 13:445-458
23. 23. Pownall HJ, Massey JB, Kusserow SK, Gotto AM Jr (1978). Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry 17:1183-1188
24. 24. Pritchard PH, McLeod R, Frohlich J, Park MC, Kudchodkar BJ, Lacko AG (1988) Lecithin:cholesterol acyltransferase in familial HDL-deficiency. Biochim Biophys Acta 958:227-234
25. Oslo and ApoA-I(P165R), which are associated with hypoalphalipoproteinemia in heterozygous carriers. J Lipid Res 40:486-494
26. 26. Hill JS, Wang KOX, Paranjape S, Dimitrijevich D, Lacko AG, Pritchard PH (1993) Expression and characterisation of recombinant human lecithin:cholesterol acyltransferase. J Lipid Res 34:1245-1251
27. 27. Cullen P, Tegelkam K, Fobker M, Kannenberg F, Assmann G (1997) Measuring cholesterol in macrophages: comparison of high performance liquid chromatography and gas liquid chromatography with enzymatic fluorometry. Anal Biochem 251:39-44
28. 28. Sorci-Thomas M, Kearns MW, Lee JP (1993) Apolipoprotein A-I domains involved in lecithin:cholesterol acyltransferase activation. Structurc:function relationships. J Biol Chem 268:21403-21409
29. 29. Gillotte KL, Davidson WS, Lund-Katz S, Rothblat GH, Phillips MC (1996) Apolipoprotein A-I structural modification and the functionality of reconstituted high density lipoprotein particles in cellular cholesterol efflux. J Biol Chem 271: 23792-23798
30. 30. Sirtori CR, Calabresi L, Franceschini G (1999) Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis 142:29-40
31. Milano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem 260:16321-16325
32. 32. Calabresi L, Franceschini G, Burkybile A, Jonas A (1997) Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer. Biochem Biophys Res Commun 232:345-349
33. FIN (Leu→Arg) mutation affects lecithin cholesterol acyltransferase activation and subclasses distribution of HDL but not cholesterol efflux from fibroblasts. Arterioscler Thromb Vasc Biol 17:3021-3032
34. 34. Minnich A, Collet X, Roghani K, Cladaras C, Hamilton RL, Fielding CJ, Zannis VI (1992) Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin:cholesterol acyltransferase activation and lipid binding. J Biol Chem 267:16553-16560
35. 35. Sorci-Thomas M, Curtiss L, Parks J, Thomas MJ, Kearns MW (1997) Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase re-activity. J Biol Chem 272:7278-7284
36. 36. Holvoct P, Zhao Z, Vanloo B, Vos R, Deridder E, Dhocst A, Taveirne J, Brouwers A, Demarsin E, Engelborghs Y, Rosseneu M, Collen D, Brasseur R (1995) Phospholipid binding and lecithin:cholesterol acyltransferase activation properties of apolipoprotein A-I variants. Biochemistry 34:13334-13342
37. 37. Rall SC, Weisgraber KH, Mahley RW, Ogawa Y, Fielding CJ, Utermann G, Haas GJ, Steinmetz A, Menzel HJ, Assmann G (1984) Abnormal lecithin-cholesterol acyltransfcrase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. J Biol Chem 259:10063-10070
38. Glessen(Pro143→Arg): a mutant that is defective in activating LCAT. Eur J Biochem 144:326-331
39. 39. Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, Segrest JP, Phillips MC, Rothblat GH (1995). Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 34:7955-7965
40. 40. Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF (1994) Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 94:1698-1705
41. Milano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol. Arterioscler Thromb Vasc Biol 17:1637-1643
42. 165→Arg). J Biol Chem 268:2616-2622
43. 43. Luchoomun J, Theret N, Clavey V, Duchateau P, Rosseneu M, Brasseur R, Denefle P, Fruchart JC, Castro GR (1994) Structural domain of apolipoprotein A-I involved in its interaction with cells. Biochim Biophys Acta 1212:319-326
44. 44. Fielding PE, Kawano M, Catapano AL, Zoppo A, Marcovina S, Fielding CJ (1994) Unique epitope of apolipoprotein A-I expressed in preβ1-high density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. Biochemistry 33: 6981-6985
45. 45. Sviridov D, Pyle L, Fidge N (1996) Identification of a sequence in apolipoprotein A-I associated with the efflux of intracellular cholesterol to human species and apolipoprotein A-I containing particles. Biochemistry 35:189-196